Haluska, Paul

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Haluska, P., Worden, F., Olmos, D., Yin, D., Schteingart, D., Batzel, G. N., Paccagnella, M. L., de Bono, J. S., Gualberto, A., & Hammer, G. D. (2010) · Cancer Chemotherapy and Pharmacology

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 197

Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment

Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 100

Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecina

LI, X., HALUSKA, P., HSIANG, Y., BHARTI, A., KUFE, D. W., & RUBIN, E. H. (1996) · Annals of the New York Academy of Sciences

Cancer therapeutics and mechanismsBioactive Compounds and Antitumor Agents

Cited by 21